Skip to content

Mechanical Thrombectomy in the Middle East and North Africa: Interim Results from the MEMENTO Registry

Mechanical Thrombectomy in the Middle East and North Africa: Interim Results from the MEMENTO Registry

Status
Enrolling by invitation
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06702787
Acronym
MEMENTO Regist
Enrollment
1500
Registered
2024-11-25
Start date
2022-03-11
Completion date
2025-09-11
Last updated
2024-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endovascular Procedures, Large Vessel Occlusion, Stroke, Stroke Acute

Keywords

Mechanical Thrombectomy, Acute Ischemic, Stroke Large Vessel Occlusion, Middle East and North Africa MENA Region, Endovascular Treatment, Cerebral Infarction, Brain Ischemia, Stroke Management, Reperfusion Therapy, Neurointervention Cerebrovascular

Brief summary

The MEMENTO (MEchanical thrMobectomy NETwork for MENA TOgether) Registry is a multicenter, prospective observational study aiming to evaluate the effectiveness, safety, and cost-effectiveness of mechanical thrombectomy (MT) in patients with acute ischemic stroke (AIS) due to large vessel occlusions (LVO) in the Middle East and North Africa (MENA) region. This interim analysis reports on the first 499 patients enrolled, assessing clinical outcomes, procedural details, and economic implications.

Detailed description

Detailed Description Stroke is a leading cause of morbidity and mortality worldwide, with a significant burden in the MENA region due to limited access to advanced stroke care therapies like mechanical thrombectomy (MT). The MEMENTO Registry seeks to collect real-world data on MT practices, outcomes, and accessibility in the MENA region to inform clinical practice and policy. The study includes AIS patients who underwent MT for confirmed LVO or medium vessel occlusion (MeVO), with or without prior intravenous thrombolysis (IV tPA), regardless of age, baseline NIHSS score, or time from symptom onset. Data collected encompass demographics, clinical characteristics, imaging findings, procedural details, outcomes at discharge and follow-up, complications, and a cost-effectiveness analysis comparing MT to standard medical care (SMC). The primary outcome is functional independence at 90 days post-procedure, defined as a modified Rankin Scale (mRS) score of 0-2.

Interventions

None listed

Sponsors

Middle East North Africa Stroke and Interventional Neurotherapies Organization
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

Adults aged 18 years and older (no upper age limit). Diagnosed with acute ischemic stroke due to confirmed large vessel occlusion (LVO) or medium vessel occlusion (MeVO). Underwent mechanical thrombectomy (MT) with or without prior intravenous thrombolysis (IV tPA). Pre-stroke modified Rankin Scale (mRS) score of 0-5. Consent to participate in the registry (by patient or legal representative).

Exclusion criteria

Absence of confirmed LVO or MeVO. Pre-stroke mRS score of 6. Known severe comorbid conditions precluding MT. Inability to obtain informed consent. Patients not treated with MT.

Design outcomes

Primary

MeasureTime frameDescription
Functional Independence at 90 Days90 days post-procedureDescription: Proportion of patients achieving a modified Rankin Scale (mRS) score of 0-2 at 90 days post-procedure.

Secondary

MeasureTime frameDescription
Complication RateImmediately post-procedure up to 7 daysIncidence of procedure-related complications (e.g., arterial dissection, vessel perforation).
Proportion of Patients Achieving TICI Score ≥2b After MTImmediately post-procedureProportion of patients achieving Thrombolysis in Cerebral Infarction (TICI) score ≥2b after MT. Scale Title: Thrombolysis in Cerebral Infarction (TICI) score Scale Range: 0 to 3 Outcome Interpretation: Higher scores indicate better outcomes, with a score of ≥2b representing successful reperfusion.
All-Cause Mortality at 90 Days90 days post-procedureProportion of patients who have died from any cause by 90 days post-procedure.
Symptomatic Intracerebral Hemorrhage (sICH) RateWithin 7 days post-procedureIncidence of symptomatic intracerebral hemorrhage (sICH) in patients post-mechanical thrombectomy (MT), defined according to the European Cooperative Acute Stroke Study III (ECASS III) criteria. sICH is identified when there is: Imaging Evidence: Any intracerebral hemorrhage (ICH) detected on neuroimaging (computed tomography \[CT\] scan or magnetic resonance imaging \[MRI\]). Clinical Deterioration: A neurological worsening characterized by an increase of ≥4 points in the National Institutes of Health Stroke Scale (NIHSS) score from baseline or leading to death.
Incremental Cost-Effectiveness Ratio (ICER) per Quality-Adjusted Life Year (QALY) GainedFrom baseline (pre-procedure) through 90 days post-procedure, with economic modeling extended to a lifetime horizon (up to 20 years)The cost-effectiveness of mechanical thrombectomy (MT) compared to standard medical care (SMC) will be assessed by calculating the Incremental Cost-Effectiveness Ratio (ICER). This involves measuring both costs and health outcomes: Costs: Using hospital billing records and resource utilization data. Effectiveness: Measuring QALYs using the EQ-5D-5L questionnaire, a standardized instrument for measuring health outcomes. ICER Calculation: Explaining that the ICER will be calculated by dividing incremental costs by incremental QALYs.
Improvement in NIHSS Score from Baseline to 24 Hours and at Follow-upBaseline, 24 hours, and up to 90 daysImprovement in National Institutes of Health Stroke Scale (NIHSS) score from baseline to 24 hours and at follow-up. Scale Title: National Institutes of Health Stroke Scale (NIHSS) Scale Range: 0 to 42 Outcome Interpretation: Lower scores indicate better outcomes, with a decrease in score representing improvement in stroke symptoms.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026